Skip to main content

Peer Review reports

From: Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine

Original Submission
29 Sep 2022 Submitted Original manuscript
28 Oct 2022 Reviewed Reviewer Report
3 Nov 2022 Author responded Author comments - Jonathan F Lovell
Resubmission - Version 2
3 Nov 2022 Submitted Manuscript version 2
14 Nov 2022 Editorially accepted
30 Nov 2022 Article published 10.1186/s12916-022-02661-1

You can find further information about peer review here.

Back to article page